BUSINESS
Efficacy of Lenalidomide in Treatment-Naïve Patients with Multiple Myeloma Confirmed in Domestic PII Study: Celgene
Celgene K.K. announced on December 9 that the efficacy of Revlimid (lenalidomide) was confirmed in a PII clinical study in treatment-naïve multiple myeloma patients. The PII study of lenalidomide is a multi-center, single-group, open-label study in which lenalidomide was administered…
To read the full story
BUSINESS
- Sanofi Bets on Immunotherapy to Delay Onset of Type 1 Diabetes
December 19, 2025
- Japan’s 1st Eylea Biosimilar to Reach Market on January 7
December 19, 2025
- Padcev-Keytruda Pair Makes Mark in Cisplatin-Eligible MIBC: Astellas
December 19, 2025
- Daiichi Sets February Launch for Japan’s 1st OTC Morning-After Pill
December 19, 2025
- Takeda’s TYK2 Inhibitor Scores PIII Win in Psoriasis Trials, Tops Otezla on Key Metrics
December 19, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





